US 11504391
Modified RNA agents with reduced off-target effect
granted A61KA61K31/713A61P
Quick answer
US patent 11504391 (Modified RNA agents with reduced off-target effect) held by Alnylam Pharmaceuticals, Inc. expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 42
- CPC classes
- A61K, A61K31/713, A61P, A61P43/00